Key facts
- Maxona Pharmaceuticals’s last known valuation is $100.9M (Jun 2025).
- It has raised $17.9M across 2 recorded rounds; the latest was Seed Round ($900K) in Jun 2025.
- Maxona Pharmaceuticals has filed 2 Form Ds with the SEC since 2021, most recently Jun 2025 ($900K sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Maxona Pharmaceuticals
Funding rounds
2 roundsAbout Maxona Pharmaceuticals
Operator of a pharmaceutical company intended to develop novel therapeutics for the treatment of moderate to severe pain without any side effects. The company leverages technology to develop non-opioid, non-NSAID, and non-CBD(cannabidiol ) analgesia using nefopam, a centrally-acting agent exerting anti-nociceptive effects via a triple neurotransmitter mechanism of action, enabling patients to get an opioid-free route of treating pain.
- Sector
- Healthcare
- HQ
- Malvern, PA, United States
- Founded
- 2015
- Employees
- 7
- Website
- maxonapharm.com/
- Ownership
- Privately Held (backing)
Maxona Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Maxona Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Maxona Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.